Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation Journal Article


Authors: Percival, M. E.; Wang, H. L.; Zhang, M. J.; Saber, W.; de Lima, M.; Litzow, M.; Kebriaei, P.; Abdel-Azim, H.; Adekola, K.; Aljurf, M.; Bacher, U.; Badawy, S. M.; Beitinjaneh, A.; Bejanyan, N.; Bhatt, V.; Byrne, M.; Cahn, J. Y.; Castillo, P.; Chao, N.; Chhabra, S.; Copelan, E.; Cutler, C.; DeFilipp, Z.; Dias, A.; Diaz, M. A.; Estey, E.; Farhadfar, N.; Frangoul, H. A.; Freytes, C. O.; Gale, R. P.; Ganguly, S.; Gowda, L.; Grunwald, M.; Hossain, N.; Kamble, R. T.; Kanakry, C. G.; Kansagra, A.; Kharfan-Dabaja, M. A.; Krem, M.; Lazarus, H. M.; Lee, J. W.; Liesveld, J. L.; Lin, R.; Liu, H.; McGuirk, J.; Munker, R.; Murthy, H. S.; Nathan, S.; Nishihori, T.; Olsson, R. F.; Palmisiano, N.; Passweg, J. R.; Prestidge, T.; Ringdén, O.; Rizzieri, D. A.; Rybka, W. B.; Savoie, M. L.; Schultz, K. R.; Seo, S.; Sharma, A.; Solh, M.; Strair, R.; van der Poel, M.; Verdonck, L. F.; Yared, J. A.; Weisdorf, D.; Sandmaier, B. M.
Article Title: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
Abstract: Acute myeloid leukemia (AML) patients often undergo allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR). We examined the effect of depth of clinical response, including incomplete count recovery (CRi) and/or measurable residual disease (MRD), in patients from the Center for International Blood and Marrow Transplantation Research (CIBMTR) registry. We identified 2492 adult patients (1799 CR and 693 CRi) who underwent alloHCT between January 1, 2007 and December 31, 2015. The primary outcome was overall survival (OS). Multivariable analysis was performed to adjust for patient-, disease-, and transplant-related factors. Baseline characteristics were similar. Patients in CRi compared to those in CR had an increased likelihood of death (HR: 1.27; 95% confidence interval: 1.13–1.43). Compared to CR, CRi was significantly associated with increased non-relapse mortality (NRM), shorter disease-free survival (DFS), and a trend toward increased relapse. Detectable MRD was associated with shorter OS, shorter DFS, higher NRM, and increased relapse compared to absence of MRD. The deleterious effects of CRi and MRD were independent. In this large CIBMTR cohort, survival outcomes differ among AML patients based on depth of CR and presence of MRD at the time of alloHCT. Further studies should focus on optimizing post-alloHCT outcomes for patients with responses less than CR. © 2021, The Author(s), under exclusive licence to Springer Nature Limited.
Journal Title: Bone Marrow Transplantation
Volume: 56
Issue: 9
ISSN: 0268-3369
Publisher: Nature Publishing Group  
Date Published: 2021-09-01
Start Page: 2108
End Page: 2117
Language: English
DOI: 10.1038/s41409-021-01261-6
PUBMED: 33864019
PROVIDER: scopus
PMCID: PMC8425595
DOI/URL:
Notes: Article -- Correction issued, see DOI 10.1038/s41409-021-01353-3 -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Richard Jirui Lin
    124 Lin